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Importance of IL-18-Induced Super
Th1 Cells for the Development of
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ABSTRACT
Th1 cells, which express IL-18R, produce IFN-γ in response to Ag and IL-2 and increase further production of
IFN-γ upon additional IL-18 stimulation. They simultaneously produce Th2 cytokines (IL-9 and IL-13), GM-CSF
and chemokines (RANTES, MIP-1α). Human Th1 cells also produce IFN-γ and IL-13 in response to anti-CD3
and IL-18. Recently, we demonstrated Th1 cells induce intrinsic type atopic asthma and dermatitis by produc-
tion of Th1- and Th2-cytokines and chemokines. Here, we review the pathological roles of Th1 cells, stimulated
with Ag and IL-18 in vivo, in the pathogenesis of allergic disorders by production of Th1 and Th2 cytokines and
chemokines. Based on this unique function of Ag- plus IL-18-stimulated Th1 cells, we proposed to designate
them as “super Th1 cells”.
KEY WORDS
allergic inflammation, atopic dermatitis, bronchial asthma, IL-18, super Th1
INTRODUCTION
Bronchial asthma is a complex syndrome character-
ized by airway hyperresponsiveness (AHR) and re-
versible airflow obstruction associated with airway in-
flammation and remodeling and occasional high se-
rum level of IgE.1-7 Th2 cells have been recognized as
inducing bronchial asthma by production of Th2 cy-
tokines.1-10 Particularly, IL-13 is suggested to play a
critical role in induction of AHR, eosinophilic infiltra-
tion, goblet cell metaplasia, and lung fibrosis.9-11 In
contrast, Th1 cells had been regarded to inhibit bron-
chial asthma by production of IFN-γ.12-14 However,
several studies have disclosed the disability of Th1
cell to suppress Th2 cell-induced AHR.15-19 On the
contrary, a combination of Th1 and Th2 cells or their
products rather augment each activity to induce air-
way inflammation and AHR.15,16,19
We demonstrated recently that OVA (Ag) plus IL-
18 acts on adoptively transferred OVA-specific mem-
ory type Th1 cells to induce airway inflammation and
AHR in a naive host mouse.20 Th1 cells, which ex-
press IL-18R, produce IFN-γ in response to OVA and
increase further IFN-γ production in response to addi-
tional IL-18 stimulation.21 Surprisingly, they simulta-
neously produce Th2 cytokines (e.g., IL-9 and IL-13),
GM-CSF and chemokines (e.g., RANTES and MIP-1)
when stimulated with OVA and IL-18.20 Human Th1
cells also produce IFN-γ and IL-13 in response to anti-
CD3 plus IL-18.22 Recently, we demonstrated Th1
cells induce intrinsic atopic dermatitis by production
of Th1 and Th2 cytokines and chemokines.23 Thus,
IL-18 has added its new function to its growing func-
tional list.24-26 Based on this unique function of Ag-
plus IL-18-stimulated Th1 cells, we proposed to desig-
nate them as “super Th1 cells”.23
THE MOLECULAR MECHANISM FOR IL-18
SECRETION
As Il18, like Il1β, lack leader sequence, Il18 product
pro-IL-18 cannot be secreted, but is stored intracellu-
larly.24,25,27,28 Many cell types exemplified by macro-
phages produce pro-IL-18 in the steady state.24,27,28
Epithelial cells lining host body, such as respiratory
epithelial cells, intestinal epithelial cells and keratino-
cytes can produce pro-IL-18 under normal conditions
as well. Pro-IL-18 needs appropriate post-translational
processing to become biologically active and to be ex-
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Fig. 1 Mechanisms involved in the processing and releas-
ing IL-18. Macrophages (Mϕ) and dendritic cels are major 
cel sources of IL-18. The cels constitutively produce pro-IL-
18. After stimulation through Tol-like receptor 4 (TLR4) and 
Fas, caspases (Casps) are activated for appropriately cleav-
age of proIL-18, resulting in the release of biologicaly active 
mature IL-18. Chymase degranulated from activated human 
mast cels can process pro-IL-18 into biologicaly active IL-
18 as wel.
Fig. 2 Super Th1 cels. When they are activated with Ag 
together with IL-18, Th1 cels become to exert their actions 
as super Th1 cels by producing both Th1 and Th2 
cytokines. Among the cytokines, IFN-γ and IL-13 are critical 
for the development of AHR and airway fibrosis, respec-
tively.
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tracellularly released (Fig.1).27,28 Caspase 1 (Casp1)
is an authentic processing enzyme for IL-18 and IL-1
β.27 Casp1 is also produced as enzymatically inactive
zymogen in the cytoplasm and needs mutual cleavage
to become active. Recently, the multiple protein com-
plex named inflammasome is verified to be the plat-
form for Casp1 activation.29 Inflammasome is com-
posed of Nod-like receptor (NLR), a cytoplasmic sen-
sor, Casp1 activation adaptor ASC, pro-Casp1 and
substrates such as pro-IL-18 and pro-IL-1β. Nalp3
NLRP3 is believed to senses extrinsic pathogen-
associated molecular patterns (PAMPs). Indeed, after
stimulation with LPS, Nalp3 inflammasome is
promptly formed, followed by rapid processing of IL-1
β andor IL-18. Thus, microbial infection induces IL-
18 and IL-1β release via activation of Nalp3 inflamma-
some. For example, in response to TLR4 agonist LPS,
hepatic tissue macrophages secrete IL-18 and IL-1β in
a manner dependent on Casp1, ASC and Nalp3.30
IL-18 processing might occur extracellularly as
well. Recent report shows that chymase, an enzyme
localized in the granules of mast cells, has capacity to
cleave pro-IL-18 into biologically active IL-18
(Fig.1).31 Since mast cells are accumulated into the
skin lesion of mice with AD-like dermatitis,23,26,32 chy-
mase from the activated mast cells might exacerbate
the skin inflammation by enhancing the local release
of biologically active IL-18.
Epithelial cells are major cell source of various pro-
allergic cytokines, such as IL-18, IL-25, TSLP and IL-
33. As they are accumulated preferentially in the in-
flammatory sites of patients with Th2 type allergic
diseases, IL-25, TSLP and IL-33 might be involved in
the development of Th2 type allergy.33-35 By contrast,
epithelium-derived IL-18 might trigger infectious type
of allergic diseases as described later, although the
mechanism for secretion of IL-18 from the epithelial
cells are still to be elucidated.36,37
SUPER TH1 CELLS AND ASTHMA
IL-18R expression levels determine the intensity of
responsiveness to IL-18 and are quite distinct among
Th cell subsets.25,26 Naïve CD4+ T cells and Th2 cells
express little IL-18R, while Th1 cells express high lev-
els of it. Consistently, the amount of IL-4 produced by
Th2 cells is not affected by additional stimulation with
IL-18. In contrast, Th1 cells produce larger amounts
of Th1 cytokines such as IFN-γ and TNF-α when ad-
ditionally stimulated through their IL-18R (Fig.2).
From these early studies IL-18 was regarded as the
Th1 response-activating cytokine. Our resent study
unveiled a second important property of IL-18 in the
adaptive immunity. IL-18 has potential to render Th1
cells to produce Th2 cytokines.20 Upon simultaneous
engagement of TCR and IL-18R, Th1 cells become to
produce abundant IL-3, IL-13 and IL-9, but still not IL-
4, in addition to the Th1 cytokines. They also produce
larger amounts of chemokines that can recruit vari-
ous pro-atopic cells, including granulocytes, macro-
phages and lymphocytes. We designate these IL-13
IL-9chemokine-producing Th1 cells as super Th1
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cells (Fig.2).
What about in vivo role of super Th1 cells? Naïve
mice transferred with OVA-specific Th2 cells that are
generated from OVA-specific naïve DO11.10 CD4+
cells by in vitro incubation under Th2 condition,
namely “Passive Th2 mice”, expectedly develop asth-
matic response upon intranasal OVA challenge.20
They develop AHR, airway eosinophillia and goblet
cell metaplasia of airway epithelial cells. Expectedly,
IL-13 blockade can protect against the development
of all of those manifestations. In contrast, “Passive
Th1 mice”, which are generated by the protocol simi-
lar to “Passive Th2 mice” except for in vitro incuba-
tion of naïve OVA-specific CD4+ cells under Th1 con-
dition, do not show any asthmatic signs andor symp-
toms after intranasal challenge with OVA alone. How-
ever, whenever challenged with OVA together with
IL-18, “Passive Th1 mice” start to succumb to AHR,
airway eosinophilia and peribronchial fibrosis, sug-
gesting the possible activation of super Th1 cells. In
contrast to Th2 type asthma observed in “Passive Th2
mice”, IL-13 blockade prevents airway eosinophilic in-
flammation and peribronchial fibrosis, partly and pro-
foundly, but entirely not AHR.37 This AHR can be pro-
tected by IFN-γ blockade. Thus, super Th1 cells
might be involved in the pathogenesis of certain
types of allergic disorders by producing both IFN-γ
and IL-13.
INFECTIOUS TYPE BRONCHIAL ASTHMA
It is well documented that microbial infection aggra-
vates andor triggers allergic diseases in human. For
example, lower respiratory infection with rhinovirus,
a common microbe relevant to cold, or with Myco-
plasma pneumoniae and Chlamydophila pneumoniae,
common bacteria causative of community-acquired
pneumonia, frequently provokes or exacerbates bron-
chial asthma in asthmatic patients.38,39 Lesional skin
infection with Staphylococcus aureus worsens the dis-
ease severity in patients with atopic dermatitis (AD).
As microbial infection sometimes evokes IL-18 secre-
tion,25,26 we may assume that microbial products
might cause local release of IL-18, which in turn trig-
gers bronchial asthma by activation of super Th1
cells. As expected, murine bronchial epithelial cells
can respond to LPS by releasing IL-18. “Passive Th1
mice” or wild-type mice immunized with OVA in Th1
adjuvant (“Active Th1 mice”) show AHR, peribron-
chial eosinophilic inflammation upon intranasal chal-
lenge with OVA in combination with LPS, a cell-wall
component of Gram-negative bacteria.37 In sharp con-
trast, IL-18 blockade can rescue “Active Th1 mice”
from these clinical manifestations after intranasal
challenge with OVA and LPS. Il18-- mice immunized
with OVA in Th1 adjuvant can evade them after being
similarly challenged.37 Thus, endogenously produced
IL-18 and exogenously administered OVA both might
activate OVA-specific super Th1 cells, leading to the
development of asthmatic manifestations in infectious
type of asthma.
ATOPIC DERMATITIS INDUCED BY TOPI-
CAL APPLICATION WITH STAPHYLOCOC-
CAL PRODUCT
Super Th1 cells are also highlighted in infectious type
of AD in mice. Consecutive and topical application of
protein A (SpA) purified from cell wall of Staphylococ-
cus aureus induces AD-like pruritic dermatitis in mice
with genetically impaired skin barrier function, NC
Nga mice.23 CD4+ T cells purified from draining
lymph nodes (DLN) of mice prior to the onset show
the characteristics of Th1 cells. These cells produce
Th1 cytokines (IFN-γ and TNF-α), but not Th2 cy-
tokine (IL-4 and IL-13) upon TCR engagement. How-
ever, CD4+ DLN cells prepared from the mice post
onset exhibit the feature as super Th1 cells. Keratino-
cytes freshly isolated from naive mice release IL-18 in
response to SpA in vitro,36 suggesting involvement of
IL-18 in the in vivo development into super Th1 cells.
In fact, IL-18 blockade and deletion of Il18 rescue
mice from the development of SpA-induced AD-like
dermatitis, concomitant with prevention of their su-
per Th1 cell development. Among cytokines pro-
duced by super Th1 cells IFN-γ and TNF-α are impor-
tant. IFN-γ or TNF-α blockade prevents the develop-
ment of this skin inflammation. Thus, IL-18-
dependent super Th1 cell development is important
for the development of this dermatitis.
CLINICAL EVIDENCE FOR IL-18
Accumulating evidence suggests positive relationship
between IL-18 levels in the lesion or circulation and
allergic diseases, such as asthma, allergic rhinitis and
AD.40-42 In particular, after inhalatory challenge test
with flour allergens patients with occupational aller-
gic asthma andor rhinitis show a significant increase
in IL-18 levels in nasal lavage fluid. Furthermore,
IL18 polymorphism that ensures higher production
of IL-18 upon appropriate stimuli is preferentially ac-
cumulated in patients with allergic disorders.43-45 Al-
though no polymorphisms differed significantly in
frequency between the control and adult asthma
groups, functional polymorphism in IL-18 is associ-
ated with severity of adult bronchial asthma.46 These
results suggest association of IL-18 with allergic dis-
order in human. However, the molecular mechanism
for IL-18 induction of differentiation from Th1 cells
into Super Th1 cells is unclear. Nonetheless, possible
therapeutics targeting IL-18 might be beneficial for
inflammatory type of allergic disorders.
CONCLUDING REMARKS
One may accept that super Th1 cells are activated
upon microbial infection of allergic lesion. What is a
super Th1 cell subset? Do super Th1 cells, like Th1
cells, require the proper epigenetic regulation? If so,
Nakanishi K et al.
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what is a transcription factor essential for the differ-
entiation into super Th1 cells, like T-betSTAT4 for
Th1 cells (Fig.2)?
Although we need further studies to settle those is-
sues, targeting super Th1 cells and super Th1-
associated cytokines might be of value in the therapy
of severe, recurrent asthma and perhaps of infectious
type allergic diseases. We previously generated hu-
man anti-human IL-18 mAb by the gene-manipulating
technique.47 This human-derived mAb targeting hu-
man IL-18 might be highlighted as a therapeutic
agent against infectious type allergic diseases as well.
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